<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02402660</url>
  </required_header>
  <id_info>
    <org_study_id>ALK001-P1002</org_study_id>
    <secondary_id>R01FD004098</secondary_id>
    <secondary_id>R01FD006016</secondary_id>
    <nct_id>NCT02402660</nct_id>
  </id_info>
  <brief_title>Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease</brief_title>
  <acronym>TEASE</acronym>
  <official_title>A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkeus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkeus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the long term safety and tolerability of ALK-001&#xD;
      (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of&#xD;
      Stargardt disease in patients between the ages of 8 and 70 years old.&#xD;
&#xD;
      Funding Source - FDA OOPD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the effects of orally-administered ALK-001 on the progression of&#xD;
      Stargardt disease (ABCA4-related). Stargardt disease is a rare genetic disorder that leads to&#xD;
      damage to the retina and results in legal blindness. Stargardt disease is caused by a&#xD;
      defective ABCA4 gene, which affects the processing of vitamin A in the eye and leads to the&#xD;
      formation of toxic vitamin A aggregates (called &quot;vitamin A dimers&quot;) in the eye. Vitamin A&#xD;
      dimers are thought to contribute to vision loss in Stargardt disease. ALK-001, the&#xD;
      investigational drug, is a chemically-modified vitamin A designed as a replacement of vitamin&#xD;
      A to prevent the formation of toxic vitamin A dimers in the eye. Trial participants will&#xD;
      receive either ALK-001 or placebo, and follow-up visits will take place periodically for up&#xD;
      to 24 months. There is currently no treatment for Stargardt disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of 24 months of daily dosing of ALK-001 assessed by Incidence and/or clinically significant changes of a combination of ocular and non-ocular adverse events</measure>
    <time_frame>From baseline to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of ALK-001 on the progression of Stargardt disease</measure>
    <time_frame>From baseline to 24 months</time_frame>
    <description>Combination of changes in atrophic lesion size, best corrected visual acuity (BCVA), and ocular assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of ALK-001 derived from the concentrations of ALK-001 and metabolites in plasma</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Stargardt Disease</condition>
  <condition>Stargardt Macular Degeneration</condition>
  <condition>Stargardt Macular Dystrophy</condition>
  <condition>Autosomal Recessive Stargardt Disease 1 (ABCA4-related)</condition>
  <arm_group>
    <arm_group_label>ALK-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily, oral administration of one capsule. See details below.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily, oral administration of one capsule. See details below.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALK-001</intervention_name>
    <description>Daily, oral administration for 24 months</description>
    <arm_group_label>ALK-001</arm_group_label>
    <other_name>C20-D3-Retinyl Acetate</other_name>
    <other_name>C20 Deuterated vitamin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily, oral administration for 24 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Simplified Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between 8 and 70 years old (inclusive), with any visual acuity&#xD;
&#xD;
          -  Has a clinical diagnosis of typical autosomal recessive Stargardt macular dystrophy&#xD;
             (STGD1)&#xD;
&#xD;
          -  Has provided a genetic report indicating at least two ABCA4 disease-causing mutations.&#xD;
             When only one ABCA4 disease-causing mutation is reported, sponsor's permission will be&#xD;
             required.&#xD;
&#xD;
          -  At least one eye (called the &quot;primary study eye&quot;) must have at least one&#xD;
             well-demarcated area of significantly reduced autofluorescence as imaged by fundus&#xD;
             autofluorescence (FAF), have decreased retinal sensitivity as measured by&#xD;
             microperimetry, or have maculopathy expected to progress over the duration of the&#xD;
             study&#xD;
&#xD;
          -  Primary study eye must have clear ocular media and adequate pupillary dilation,&#xD;
             including no allergy to dilating eyedrops, to permit good quality retinal imaging&#xD;
&#xD;
          -  Healthy as judged by investigator&#xD;
&#xD;
          -  Able and willing to comply with study requirements, restrictions and instructions and&#xD;
             is likely to complete the 24-month study&#xD;
&#xD;
          -  Has signed and dated the informed consent forms (or assent where appropriate) to&#xD;
             participate&#xD;
&#xD;
          -  Female of childbearing potential has signed the informed consent about birth defects&#xD;
             or attestation on contraception requirements&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Has taken disallowed items (supplement containing vitamin A or beta-carotene,&#xD;
             liver-based products, or prescription oral retinoid medications) over the past 30 days&#xD;
&#xD;
          -  Is lactating, pregnant, or has a positive serum or urine pregnancy test at screening&#xD;
             or at randomization&#xD;
&#xD;
          -  Has concurrent medical condition or history, which in the opinion of the investigator,&#xD;
             is likely to prevent compliance with the protocol and/or interfere with absorption of&#xD;
             ALK-001 or study procedures&#xD;
&#xD;
          -  Has clinically significant abnormal laboratory result(s) at screening&#xD;
&#xD;
          -  Has active or historical acute or chronic liver disorder&#xD;
&#xD;
          -  Has active or historical ocular disorder in the primary study eye that, in the opinion&#xD;
             of the investigator, may confound assessment of the retina morphologically or&#xD;
             functionally (this could include for example cataract surgery within the past 6&#xD;
             months, choroidal neovascularization (CNV), glaucoma, recurring uveitis, diabetic&#xD;
             retinopathy, other retinal disease, etc.)&#xD;
&#xD;
          -  Has had intraocular surgery or injections in the primary study eye within 90 days of&#xD;
             the screening visit&#xD;
&#xD;
          -  Has a clinically significant abnormal electrocardiogram (ECG), or has a corrected QT&#xD;
             interval (QTc) that is 450 ms or greater&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Scholl, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonide Saad, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alkeus Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonide Saad, PhD</last_name>
    <phone>800-287-2755</phone>
    <email>trials@alkeus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles - Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Gorin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Nusinowitz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vitreoretinal Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Kay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami - Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Byron Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins - Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center - Harkness Eye Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Tsang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah - Moran Eye Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin - Eye Institute</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alkeuspharma.com/stargardt.html</url>
    <description>Please leave your name if you would like to be contacted to discuss this trial</description>
  </link>
  <reference>
    <citation>Ma L, Kaufman Y, Zhang J, Washington I. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem. 2011 Mar 11;286(10):7966-7974. doi: 10.1074/jbc.M110.178657. Epub 2010 Dec 14.</citation>
    <PMID>21156790</PMID>
  </reference>
  <reference>
    <citation>Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011 Mar 11;286(10):7958-7965. doi: 10.1074/jbc.M110.178640. Epub 2010 Nov 12.</citation>
    <PMID>21075840</PMID>
  </reference>
  <reference>
    <citation>Mihai DM, Jiang H, Blaner WS, Romanov A, Washington I. The retina rapidly incorporates ingested C20-D₃-vitamin A in a swine model. Mol Vis. 2013 Jul 25;19:1677-83. Print 2013.</citation>
    <PMID>23914132</PMID>
  </reference>
  <reference>
    <citation>Charbel Issa P, Barnard AR, Herrmann P, Washington I, MacLaren RE. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8415-20. doi: 10.1073/pnas.1506960112. Epub 2015 Jun 23.</citation>
    <PMID>26106163</PMID>
  </reference>
  <reference>
    <citation>Saad L, Washington I. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies? Adv Exp Med Biol. 2016;854:355-61. doi: 10.1007/978-3-319-17121-0_47.</citation>
    <PMID>26427432</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Stargardt Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Retinol acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

